Article

Novel anti-collagenolytic regimen applied for treating stage IV DLK

A new treatment strategy consisting of oral doxycycline and topical sodium citrate 10% may have a positive role in the treatment of post-LASIK inflammatory conditions characterized by increased collagenolytic activities, said Elias F. Jarade, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Related Content
New dataset offers insights to improve cataract surgery care
May 3rd 2025

New dataset offers insights to improve cataract surgery care

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

EMA CHMP issues positive opinion for teprotumumab (Tepezza) marketing authorization application
May 3rd 2025

EMA CHMP issues positive opinion for teprotumumab (Tepezza) marketing authorization application

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Positive interim pilot clinical trial results of PKY-2101
May 2nd 2025

Positive interim pilot clinical trial results of PKY-2101

Retinal thinning may serve as early biomarker of genetic risk for schizophrenia
May 2nd 2025

Retinal thinning may serve as early biomarker of genetic risk for schizophrenia

© 2025 MJH Life Sciences

All rights reserved.